Keywords
Food consumption
Intestinal permeability
Intestinal microbiota
Polymedication
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To investigate the association between food consumption and the presence of signs and symptoms suggestive of dysbiosis and intestinal hyperpermeability in polypharmacy users. Methods: A cross-sectional study was conducted with adult and elderly polypharmacy users, using an electronic questionnaire. Signs and symptoms of intestinal hyperpermeability were assessed using a validated instrument and classified as “non-priority” (low/mild) and “priority” (moderate/high). Nutritional status was assessed by body mass index, and food consumption was classified according to the VIGITEL methodology. Statistical analyses were performed in Stata 17.0, using chi-square tests, Fisher's exact test, and simple logistic regression, adopting a significance level of 5%. Results: A total of 167 individuals participated, mostly women (76.65%) and over 60 years of age (38.92%), with a prevalence of overweight (65.27%). A significant association was observed between priority for treatment of intestinal hyperpermeability and regular consumption of sweets, pasta, and soft drinks (OR = 2.60; 95% CI: 1.0–6.78; p = 0.045), as well as with the amount of coffee consumed (OR = 2.49; 95% CI: 1.09–5.72; p = 0.028). Anti-inflammatory drugs and analgesics also showed a significant association (p < 0.001). Conclusion: The consumption of sweets, sugary drinks, pasta, coffee, canned foods, and sausages was associated with the occurrence of dysbiosis and intestinal hyperpermeability in individuals using polypharmacy.
References
ALMEIDA LB, et al. Disbiose intestinal: revisão. Revista Brasileira de Nutrição Clínica, 2009; 24(1): 58-65.
APARECIDA GARDA CM, et al. Fatores associados à constipação intestinal em um grupo de idosos de um município do Sudoeste Paranaense. Revista Faz Ciência, 2024; 26(43).
ARNAUD M. Mild dehydration: a risk factor of constipation? European Journal of Clinical Nutrition, 2003; 57(Suppl 2): S88-S95.
ASENSI TM, et al. Low-Grade Inflammation and Ultra-Processed Foods Consumption: A Review. Nutrients, 2023; 15(6): 1546.
BANERJEE S, et al. Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation. Mucosal Immunology, 2016; 9(6): 1418-1428.
BERNAUD FSR, RODRIGUES TC. Fibra alimentar: ingestão adequada e efeitos sobre a saúde do metabolismo. Arquivos Brasileiros de Endocrinologia & Metabologia, 2013; 57(6): 397-405.
BROWN S, et al. Effect of coffee on distal colon function. Gut, 1990; 31(4): 450-453.
CANDIDO GZ, et al. A influência dos fármacos sobre a microbiota gastrointestinal humana: uma revisão de literatura. Brazilian Journal of Implantology and Health Sciences, 2024; 6(9): 1382-1404.
CANANI RB, et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World Journal of Gastroenterology, 2011; 17(12): 1519-1528.
DALTON SO, et al. Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Tract Bleeding. Archives of Internal Medicine, 2003; 163(1): 59.
ELIZABETH L, et al. Ultra-Processed Foods and Health Outcomes: A Narrative Review. Nutrients, 2020; 12(7).
ENGEN PA, et al. The Gastrointestinal Microbiome: Alcohol Effects on the Composition of Intestinal Microbiota. Alcohol Research: Current Reviews, 2015; 37(2): 223-236.
FU J, et al. Dietary Fiber Intake and Gut Microbiota in Human Health. Microorganisms, 2022; 10(12): 2507.
HILLS RD JR, et al. Gut Microbiome: Profound Implications for Diet and Disease. Kompass Nutrition &
Dietetics, 2022; 1-16.
HOU K, et al. Microbiota in health and diseases. Signal Transduction and Targeted Therapy, 2022; 7(1): 135.
IACOB S, IACOB DG. Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis. Frontiers in Microbiology, 2019; 10: 1830.
INSTITUTE OF MEDICINE. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. Washington, DC: National Academies Press, 2005; 638p.
KAYAMA H, et al. Interaction Between the Microbiota, Epithelia, and Immune Cells in the Intestine. Annual Review of Immunology, 2020; 38: 23-48.
KÖNIG J, et al. Human Intestinal Barrier Function in Health and Disease. Clinical and Translational Gastroenterology, 2016; 7(10): e196.
LEWIS SJ, HEATON KW. Stool form scale as a useful guide to intestinal transit time. Scandinavian Journal of Gastroenterology, 1997; 32(9): 920-924.
LOPES ABB, et al. A relação entre a disbiose intestinal causada por alimentos ultraprocessados e a doença de Alzheimer. Brazilian Journal of Health Review, 2024; 7(9): e75954.
LOUZADA MLDC, et al. Consumo de alimentos ultraprocessados no Brasil: distribuição e evolução temporal 2008-2018. Revista de Saúde Pública, 2023; 57: 12.
MASEDA D, RICCIOTTI E. NSAID-Gut Microbiota Interactions. Frontiers in Pharmacology, 2020; 11: 1153.
MELO BRC, OLIVEIRA RSB. Prevalência de Disbiose Intestinal e sua relação com doenças crônicas não transmissíveis em estudantes de uma Instituição de Ensino Superior de Fortaleza - CE. Revista Brasileira de Obesidade, Nutrição e Emagrecimento, 2018; 12(74): 767-775.
MONTEIRO CA. Ultra-processed foods: what they are and how to identify them. Public Health Nutrition, 2019; 22(5): 936-941.
MORAES ACF, et al. Microbiota intestinal e risco cardiometabólico: mecanismos e modulação dietética. Arquivos Brasileiros de Endocrinologia & Metabologia, 2014; 58(4): 317-327.
NASCIMENTO RCRM, et al. Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System. Revista de Saúde Pública, 2017; 51(Suppl 2): 19s.
NILSON E. Alimentos ultraprocessados e seus riscos à cultura alimentar e à saúde. Revista de Alimentação e Cultura das Américas, 2022; 3(2): 133-146.
OLIVEIRA RKG, et al. Consumption of in natura and ultra-processed foods in adults: an analysis of social, metabolic, and lifestyle determinants. Revista Brasileira de Epidemiologia, 2024; 27: e240018.
PEIXOTO JS, et al. Riscos da interação droga-nutriente em idosos de instituição de longa permanência. Revista Gaúcha de Enfermagem, 2012; 33(3): 156-164.
PEREIRA KG, et al. Estado nutricional e consumo alimentar de idosos do município de Palmeira das Missões-RS. Revista Brasileira de Epidemiologia, 2017; 20(2): 335-344.
ROGERS MAM, ARONOFF DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clinical Microbiology and Infection, 2016; 22(2): 178.e1-178.e9.
SECOLI SR. Polifarmácia: interações e reações adversas no uso de medicamentos por idosos. Revista Brasileira de Enfermagem, 2010; 63(1): 136-140.
SILVA CPW, et al. A disbiose intestinal como fator de risco na alteração psicológica depressiva. Brazilian Journal of Health Review, 2024; 7(2): e67755.
SZYNAL K, et al. Alimentos processados e aditivos alimentares no contexto da disbiose e suas consequências para a saúde. Advancements of Microbiology, 2021; 60(3): 223-230.
TICINESI A, et al. Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Scientific Reports, 2017; 7(1): 1114.
WANG ZT, et al. Correlation between gastroesophageal reflux disease and small intestinal bacterial overgrowth: Analysis of intestinal microbiome and metabolic characteristics. Journal of Inflammation Research, 2025; 18: 33-51.
WORLD HEALTH ORGANIZATION. 2019. Medication Safety in Polypharmacy. Disponível em: https://www.who.int/docs/default-source/patient-safety/who-uhc-sds-2019-11-eng.pdf. Acessado em: 13 de junho de 2025.